Aimovig®displays superiority over topiramate in migraine study
Amgen announces positive results from the first and only randomised, double-blind, head-to-head study comparing Aimovig® to topiramate.
List view / Grid view
Amgen announces positive results from the first and only randomised, double-blind, head-to-head study comparing Aimovig® to topiramate.
The FDA has approved Aimovig for the preventive treatment of a migraine in adults. The treatment is given by once-monthly self-injections...